Hanshang Group Co., Ltd. (SHA:600774)
China · Delayed Price · Currency is CNY 7.32
-0.07 (-0.95%)
Aug 21, 2026, 3:00 PM CST
Hanshang Group Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 1,002 | 1,032 | 1,175 | 1,390 | 1,387 | 1,475 |
Revenue Growth | -8.58% | -12.23% | -15.41% | 0.19% | -5.98% | 197.91% |
Gross Profit Gross Profit Growth | 466.69 | 486.95 | 647.42 | 845.88 | 873.24 | 920.51 |
Operating Income Operating Income Growth | -12.07 | -5.82 | 20.04 | 92.04 | 83.03 | 130.6 |
Net Income Net Income Growth | -183.05 | -174.83 | -14.59 | 61.21 | 90.33 | 85.68 |
Earnings Per Share EPS Growth | -0.62 | -0.59 | -0.05 | 0.21 | 0.31 | 0.35 |
EPS Growth | - | - | - | -32.23% | -11.81% | 73.25% |
| Fiscal Year | FY 2025 |
|---|---|
| Period Ending | Dec '25 Dec 31, 2025 |
Commercial Operations Division Commercial Operations Division Growth | 131.36 |
Exhibition Business Division Exhibition Business Division Growth | 58.11 |
Pharmaceuticals and Medical Devices Division Pharmaceuticals and Medical Devices Division Growth | 802.29 |
Other Divisions Other Divisions Growth | 39.93 |
Total Total Growth | 1,032 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 133.1 | 155.24 | 135.79 | 142.98 | 117.97 | 272.21 |
Total Debt Total Debt Growth | 756.88 | 765.02 | 851.63 | 901.3 | 897.37 | 781.29 |
Net Cash (Debt) Net Cash Growth | -623.78 | -609.78 | -715.84 | -758.32 | -779.39 | -509.08 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -2.10 | -2.06 | -2.45 | -2.57 | -2.64 | -2.06 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 133.92 | 113.49 | 192.78 | 247.18 | 242.35 | 333 |
Capital Expenditures CapEx Growth | -26.63 | -31.16 | -60.5 | -137.26 | -231.15 | -111.38 |
Free Cash Flow Free Cash Flow Growth | 107.29 | 82.33 | 132.28 | 109.92 | 11.19 | 221.62 |
Free Cash Flow Growth | -3.55% | -37.76% | 20.34% | 882.06% | -94.95% | 684.10% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 46.57% | 47.20% | 55.08% | 60.87% | 62.96% | 62.40% |
Operating Margin | -1.21% | -0.56% | 1.70% | 6.62% | 5.99% | 8.85% |
Pretax Margin | -17.30% | -15.58% | -0.47% | 5.31% | 6.80% | 6.76% |
Profit Margin | -18.27% | -16.95% | -1.24% | 4.41% | 6.51% | 5.81% |
FCF Margin | 10.71% | 7.98% | 11.25% | 7.91% | 0.81% | 15.02% |
| Fiscal Year | FY 2022 | FY 2021 |
|---|---|---|
| Period Ending | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Dividend Per Share Dividend Per Share Growth | 0.060 | 0.100 |
Dividend Per Share Growth | -40.00% | - |
Dividend Yield | 0.53% | 0.61% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 23, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | 46.56 | 36.47 | 57.37 |
P/FCF Ratio | 19.72 | 32.08 | 16.36 | 25.93 | 294.32 | 22.18 |
PS Ratio | 2.11 | 2.56 | 1.84 | 2.05 | 2.38 | 3.33 |